CS
PACB icon

Credit Suisse’s Pacific Biosciences PACB Stock Holding History

Credit Suisse’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.22M Buy
325,232
+4,533
+1% +$26.5K ﹤0.01% 2148
2023
Q4 		$3.15M Buy
320,699
+49,683
+18% +$406K ﹤0.01% 1614
2023
Q3 		$2.26M Buy
271,016
+1,218
+0.5% +$13.9K ﹤0.01% 1750
2023
Q2 		$3.59M Buy
269,798
+44,505
+20% +$541K ﹤0.01% 1553
2023
Q1 		$2.61M Buy
225,293
+9,645
+4% +$95.9K ﹤0.01% 1716
2022
Q4 		$1.76M Sell
215,648
-11,624
-5% -$100K ﹤0.01% 1958
2022
Q3 		$1.32M Buy
227,272
+1,099
+0.5% +$6.31K ﹤0.01% 2125
2022
Q2 		$999K Sell
226,173
-20,081
-8% -$122K ﹤0.01% 2385
2022
Q1 		$2.24M Buy
246,254
+37,207
+18% +$428K ﹤0.01% 2001
2021
Q4 		$4.28M Sell
209,047
-45,296
-18% -$1.09M ﹤0.01% 2147
2021
Q3 		$6.5M Buy
254,343
+32,716
+15% +$969K ﹤0.01% 1852
2021
Q2 		$7.75M Sell
221,627
-6,878
-3% -$200K ﹤0.01% 1734
2021
Q1 		$7.61M Sell
228,505
-47,136
-17% -$1.65M ﹤0.01% 1767
2020
Q4 		$7.15M Buy
275,641
+116,126
+73% +$1.97M ﹤0.01% 1811
2020
Q3 		$1.57M Buy
159,515
+25,975
+19% +$150K ﹤0.01% 2605
2020
Q2 		$461K Sell
133,540
-919,933
-87% -$3.13M ﹤0.01% 3377
2020
Q1 		$3.22M Buy
1,053,473
+548,503
+109% +$2.25M ﹤0.01% 1799
2019
Q4 		$2.6M Buy
504,970
+2,287
+0.5% +$11.6K ﹤0.01% 2401
2019
Q3 		$2.59M Sell
502,683
-407,022
-45% -$2.28M ﹤0.01% 2283
2019
Q2 		$5.5M Buy
909,705
+271,058
+42% +$1.9M ﹤0.01% 1695
2019
Q1 		$4.62M Buy
638,647
+380,722
+148% +$2.75M ﹤0.01% 1767
2018
Q4 		$1.91M Buy
257,925
+199,313
+340% +$1.26M ﹤0.01% 2283
2018
Q3 		$318K Sell
58,612
-19,415
-25% -$83.3K ﹤0.01% 3494
2018
Q2 		$277K Sell
78,027
-3,618
-4% -$10K ﹤0.01% 3652
2018
Q1 		$167K Buy
81,645
+8,791
+12% +$22.8K ﹤0.01% 3730
2017
Q4 		$191K Sell
72,854
-36,263
-33% -$127K ﹤0.01% 3755
2017
Q3 		$572K Buy
109,117
+54,402
+99% +$234K ﹤0.01% 3466
2017
Q2 		$195K Sell
54,715
-10,178
-16% -$41K ﹤0.01% 3628
2017
Q1 		$335K Sell
64,893
-21,229
-25% -$104K ﹤0.01% 3482
2016
Q4 		$327K Sell
86,122
-34,990
-29% -$254K ﹤0.01% 3618
2016
Q3 		$1.09M Buy
121,112
+24,408
+25% +$204K ﹤0.01% 2887
2016
Q2 		$680K Buy
96,704
+27,308
+39% +$249K ﹤0.01% 3232
2016
Q1 		$589K Buy
69,396
+24,588
+55% +$242K ﹤0.01% 3132
2015
Q4 		$589K Buy
44,808
+5,730
+15% +$51.4K ﹤0.01% 3248
2015
Q3 		$144K Sell
39,078
-116,619
-75% -$570K ﹤0.01% 4033
2015
Q2 		$897K Buy
155,697
+85,232
+121% +$493K ﹤0.01% 3281
2015
Q1 		$411K Sell
70,465
-62,147
-47% -$429K ﹤0.01% 3673
2014
Q4 		$1.04M Buy
132,612
+85,737
+183% +$549K ﹤0.01% 3106
2014
Q3 		$230K Sell
46,875
-62,166
-57% -$325K ﹤0.01% 4070
2014
Q2 		$674K Sell
109,041
-51,884
-32% -$260K ﹤0.01% 3617
2014
Q1 		$861K Buy
160,925
+86,914
+117% +$549K ﹤0.01% 3250
2013
Q4 		$387K Sell
74,011
-78,102
-51% -$359K ﹤0.01% 3915
2013
Q3 		$840K Buy
152,113
+109,346
+256% +$380K ﹤0.01% 3095
2013
Q2 		$109K Buy
+42,767
New +$106K ﹤0.01% 4005

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Credit Suisse's PACB Position: Q1 2024 in Review

Credit Suisse increased its Pacific Biosciences (PACB) stake by 1.4% in Q1 2024, buying an estimated $26.5K and bringing the position to 325,232 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Credit Suisse first reported a position in PACB in Q2 2013 and has held it in 44 quarters since. The position peaked at $7.75M in Q2 2021. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Credit Suisse held 325,232 shares of Pacific Biosciences worth $1.22M as of Q1 2024.
  • Credit Suisse bought 4,533 Pacific Biosciences shares in Q1 2024, an estimated $26.5K.
  • Pacific Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2148 holding.
  • Credit Suisse first reported a position in Pacific Biosciences in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Pacific Biosciences position peaked at $7.75M in Q2 2021.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.